Intrinsic value of NuVasive - NUVA

Previous Close

$48.21

  Intrinsic Value

$37.84

stock screener

  Rating & Target

sell

-22%

Previous close

$48.21

 
Intrinsic value

$37.84

 
Up/down potential

-22%

 
Rating

sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of NUVA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

Please visit our new site that uses elements of artificial intelligence for stock valuation: artificial intelligence value of NuVasive (NUVA) stock.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  18.62
  2.90
  3.11
  3.30
  3.47
  3.62
  3.76
  3.88
  4.00
  4.10
  4.19
  4.27
  4.34
  4.41
  4.47
  4.52
  4.57
  4.61
  4.65
  4.68
  4.72
  4.74
  4.77
  4.79
  4.81
  4.83
  4.85
  4.86
  4.88
  4.89
  4.90
Revenue, $m
  962
  990
  1,021
  1,054
  1,091
  1,130
  1,173
  1,219
  1,267
  1,319
  1,374
  1,433
  1,495
  1,561
  1,631
  1,705
  1,782
  1,865
  1,951
  2,043
  2,139
  2,240
  2,347
  2,460
  2,578
  2,703
  2,834
  2,972
  3,117
  3,269
  3,429
Variable operating expenses, $m
 
  818
  842
  868
  897
  928
  961
  996
  1,034
  1,074
  1,117
  1,114
  1,162
  1,214
  1,268
  1,325
  1,386
  1,450
  1,517
  1,588
  1,663
  1,742
  1,825
  1,912
  2,005
  2,101
  2,203
  2,311
  2,423
  2,542
  2,666
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  839
  818
  842
  868
  897
  928
  961
  996
  1,034
  1,074
  1,117
  1,114
  1,162
  1,214
  1,268
  1,325
  1,386
  1,450
  1,517
  1,588
  1,663
  1,742
  1,825
  1,912
  2,005
  2,101
  2,203
  2,311
  2,423
  2,542
  2,666
Operating income, $m
  124
  172
  179
  186
  194
  203
  212
  223
  233
  245
  257
  319
  333
  347
  363
  379
  397
  415
  434
  455
  476
  499
  522
  547
  574
  601
  631
  661
  694
  727
  763
EBITDA, $m
  227
  270
  278
  287
  297
  308
  320
  332
  345
  359
  375
  391
  407
  425
  444
  465
  486
  508
  532
  557
  583
  611
  640
  670
  703
  737
  772
  810
  849
  891
  935
Interest expense (income), $m
  13
  20
  21
  21
  22
  24
  25
  26
  27
  29
  30
  32
  34
  35
  37
  40
  42
  44
  46
  49
  52
  55
  58
  61
  64
  68
  71
  75
  79
  83
  88
Earnings before tax, $m
  65
  152
  158
  165
  172
  179
  188
  197
  206
  216
  227
  287
  299
  312
  325
  340
  355
  371
  388
  406
  424
  444
  465
  487
  510
  534
  559
  586
  614
  644
  675
Tax expense, $m
  30
  41
  43
  44
  46
  48
  51
  53
  56
  58
  61
  77
  81
  84
  88
  92
  96
  100
  105
  109
  115
  120
  125
  131
  138
  144
  151
  158
  166
  174
  182
Net income, $m
  37
  111
  115
  120
  125
  131
  137
  144
  150
  158
  166
  209
  218
  228
  238
  248
  259
  271
  283
  296
  310
  324
  339
  355
  372
  390
  408
  428
  448
  470
  493

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  154
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,571
  1,458
  1,503
  1,553
  1,607
  1,665
  1,727
  1,795
  1,866
  1,943
  2,024
  2,110
  2,202
  2,299
  2,402
  2,510
  2,625
  2,746
  2,874
  3,008
  3,150
  3,300
  3,457
  3,623
  3,797
  3,981
  4,174
  4,377
  4,590
  4,815
  5,051
Adjusted assets (=assets-cash), $m
  1,417
  1,458
  1,503
  1,553
  1,607
  1,665
  1,727
  1,795
  1,866
  1,943
  2,024
  2,110
  2,202
  2,299
  2,402
  2,510
  2,625
  2,746
  2,874
  3,008
  3,150
  3,300
  3,457
  3,623
  3,797
  3,981
  4,174
  4,377
  4,590
  4,815
  5,051
Revenue / Adjusted assets
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
  0.679
Average production assets, $m
  279
  287
  296
  306
  316
  328
  340
  353
  367
  383
  399
  416
  434
  453
  473
  494
  517
  541
  566
  592
  620
  650
  681
  713
  748
  784
  822
  862
  904
  948
  995
Working capital, $m
  332
  246
  254
  263
  272
  281
  292
  303
  316
  328
  342
  357
  372
  389
  406
  424
  444
  464
  486
  509
  533
  558
  584
  613
  642
  673
  706
  740
  776
  814
  854
Total debt, $m
  626
  587
  613
  641
  672
  706
  742
  780
  821
  865
  912
  961
  1,014
  1,070
  1,129
  1,191
  1,257
  1,326
  1,399
  1,477
  1,558
  1,644
  1,734
  1,829
  1,930
  2,035
  2,146
  2,262
  2,385
  2,514
  2,649
Total liabilities, $m
  876
  837
  863
  891
  922
  956
  992
  1,030
  1,071
  1,115
  1,162
  1,211
  1,264
  1,320
  1,379
  1,441
  1,507
  1,576
  1,649
  1,727
  1,808
  1,894
  1,984
  2,079
  2,180
  2,285
  2,396
  2,512
  2,635
  2,764
  2,899
Total equity, $m
  695
  621
  640
  661
  684
  709
  736
  764
  795
  828
  862
  899
  938
  979
  1,023
  1,069
  1,118
  1,170
  1,224
  1,282
  1,342
  1,406
  1,473
  1,543
  1,618
  1,696
  1,778
  1,864
  1,955
  2,051
  2,152
Total liabilities and equity, $m
  1,571
  1,458
  1,503
  1,552
  1,606
  1,665
  1,728
  1,794
  1,866
  1,943
  2,024
  2,110
  2,202
  2,299
  2,402
  2,510
  2,625
  2,746
  2,873
  3,009
  3,150
  3,300
  3,457
  3,622
  3,798
  3,981
  4,174
  4,376
  4,590
  4,815
  5,051
Debt-to-equity ratio
  0.901
  0.940
  0.960
  0.970
  0.980
  0.990
  1.010
  1.020
  1.030
  1.050
  1.060
  1.070
  1.080
  1.090
  1.100
  1.110
  1.120
  1.130
  1.140
  1.150
  1.160
  1.170
  1.180
  1.190
  1.190
  1.200
  1.210
  1.210
  1.220
  1.230
  1.230
Adjusted equity ratio
  0.382
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426
  0.426

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  37
  111
  115
  120
  125
  131
  137
  144
  150
  158
  166
  209
  218
  228
  238
  248
  259
  271
  283
  296
  310
  324
  339
  355
  372
  390
  408
  428
  448
  470
  493
Depreciation, amort., depletion, $m
  103
  98
  100
  101
  103
  105
  107
  110
  112
  115
  117
  72
  75
  78
  82
  85
  89
  93
  98
  102
  107
  112
  117
  123
  129
  135
  142
  149
  156
  163
  171
Funds from operations, $m
  51
  209
  215
  221
  228
  236
  244
  253
  262
  272
  283
  281
  293
  306
  319
  333
  348
  364
  381
  398
  417
  436
  457
  478
  501
  525
  550
  577
  604
  634
  664
Change in working capital, $m
  -105
  7
  8
  8
  9
  10
  11
  11
  12
  13
  14
  15
  15
  16
  17
  18
  19
  20
  22
  23
  24
  25
  27
  28
  29
  31
  33
  34
  36
  38
  40
Cash from operations, $m
  156
  202
  207
  213
  219
  226
  234
  242
  250
  259
  269
  267
  278
  289
  302
  315
  329
  344
  359
  375
  393
  411
  430
  450
  471
  494
  517
  542
  568
  596
  624
Maintenance CAPEX, $m
  0
  -48
  -49
  -51
  -53
  -55
  -57
  -59
  -61
  -63
  -66
  -69
  -72
  -75
  -78
  -82
  -85
  -89
  -93
  -98
  -102
  -107
  -112
  -117
  -123
  -129
  -135
  -142
  -149
  -156
  -163
New CAPEX, $m
  -94
  -8
  -9
  -10
  -11
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -23
  -24
  -25
  -27
  -28
  -29
  -31
  -33
  -34
  -36
  -38
  -40
  -42
  -44
  -46
Cash from investing activities, $m
  -305
  -56
  -58
  -61
  -64
  -66
  -69
  -72
  -75
  -78
  -82
  -86
  -90
  -94
  -98
  -103
  -108
  -113
  -118
  -125
  -130
  -136
  -143
  -150
  -157
  -165
  -173
  -182
  -191
  -200
  -209
Free cash flow, $m
  -149
  146
  149
  152
  156
  160
  165
  170
  175
  181
  187
  181
  188
  195
  203
  212
  221
  231
  241
  251
  263
  275
  287
  300
  314
  329
  344
  361
  378
  396
  414
Issuance/(repayment) of debt, $m
  83
  23
  26
  28
  31
  33
  36
  39
  41
  44
  47
  50
  53
  56
  59
  62
  66
  69
  73
  77
  81
  86
  90
  95
  100
  105
  111
  117
  123
  129
  135
Issuance/(repurchase) of shares, $m
  30
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  111
  23
  26
  28
  31
  33
  36
  39
  41
  44
  47
  50
  53
  56
  59
  62
  66
  69
  73
  77
  81
  86
  90
  95
  100
  105
  111
  117
  123
  129
  135
Total cash flow (excl. dividends), $m
  -39
  169
  175
  181
  187
  194
  201
  208
  216
  225
  234
  230
  240
  251
  262
  274
  287
  300
  314
  329
  344
  360
  377
  395
  414
  434
  455
  477
  500
  524
  550
Retained Cash Flow (-), $m
  17
  -18
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -35
  -37
  -39
  -41
  -44
  -46
  -49
  -52
  -54
  -57
  -60
  -64
  -67
  -71
  -74
  -78
  -82
  -86
  -91
  -96
  -101
Prev. year cash balance distribution, $m
 
  92
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  243
  156
  160
  164
  169
  174
  180
  186
  192
  199
  194
  201
  210
  219
  228
  238
  248
  260
  271
  284
  297
  310
  325
  340
  356
  373
  391
  409
  429
  449
Discount rate, %
 
  4.90
  5.15
  5.40
  5.67
  5.96
  6.25
  6.57
  6.89
  7.24
  7.60
  7.98
  8.38
  8.80
  9.24
  9.70
  10.19
  10.70
  11.23
  11.79
  12.38
  13.00
  13.65
  14.33
  15.05
  15.80
  16.59
  17.42
  18.29
  19.21
  20.17
PV of cash for distribution, $m
 
  231
  141
  136
  132
  126
  121
  115
  109
  103
  96
  83
  77
  70
  63
  57
  50
  44
  38
  33
  27
  23
  19
  15
  12
  9
  7
  5
  4
  3
  2
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

FINANCIAL RATIOS  of  NuVasive (NUVA)

Valuation Ratios
P/E Ratio 65.7
Price to Sales 2.5
Price to Book 3.5
Price to Tangible Book
Price to Cash Flow 15.6
Price to Free Cash Flow 39.2
Growth Rates
Sales Growth Rate 18.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -13%
Cap. Spend. - 3 Yr. Gr. Rate 14.4%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 81.2%
Total Debt to Equity 90.1%
Interest Coverage 6
Management Effectiveness
Return On Assets 3.1%
Ret/ On Assets - 3 Yr. Avg. 2.9%
Return On Total Capital 3.1%
Ret/ On T. Cap. - 3 Yr. Avg. 2.6%
Return On Equity 5.3%
Return On Equity - 3 Yr. Avg. 4.1%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 75.1%
Gross Margin - 3 Yr. Avg. 75.7%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 16.9%
Operating Margin 12.8%
Oper. Margin - 3 Yr. Avg. 10.8%
Pre-Tax Margin 6.8%
Pre-Tax Margin - 3 Yr. Avg. 6.4%
Net Profit Margin 3.8%
Net Profit Margin - 3 Yr. Avg. 3.3%
Effective Tax Rate 46.2%
Eff/ Tax Rate - 3 Yr. Avg. 8.2%
Payout Ratio 0%

NUVA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NUVA stock intrinsic value calculation we used $962 million for the last fiscal year's total revenue generated by NuVasive. The default revenue input number comes from 2016 income statement of NuVasive. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NUVA stock valuation model: a) initial revenue growth rate of 2.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.9%, whose default value for NUVA is calculated based on our internal credit rating of NuVasive, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of NuVasive.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NUVA stock the variable cost ratio is equal to 82.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for NUVA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for NuVasive.

Corporate tax rate of 27% is the nominal tax rate for NuVasive. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NUVA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NUVA are equal to 29%.

Life of production assets of 5.8 years is the average useful life of capital assets used in NuVasive operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NUVA is equal to 24.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $695 million for NuVasive - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 51.633 million for NuVasive is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of NuVasive at the current share price and the inputted number of shares is $2.5 billion.

RELATED COMPANIES Price Int.Val. Rating
ZBH Zimmer Biomet 120.48 46.72  str.sell
GMED Globus Medical 48.22 18.13  str.sell
OFIX Orthofix Inter 53.93 59.47  hold
KTWO K2M Group Hold 19.33 0.80  str.sell
RTIX RTI Surgical 4.65 1.98  str.sell
SYK Stryker 159.87 99.27  sell
SPNE SeaSpine Holdi 9.92 2.08  str.sell
EXAC Exactech 49.25 5.63  str.sell

COMPANY NEWS

▶ John DeFord To Join NuVasive Board Of Directors   [Feb-08-18 04:05PM  PR Newswire]
▶ Why Mizuho Securities Upgraded Teva Pharmaceutical to a Buy   [Jan-12-18 09:45AM  Market Realist]
▶ Here's What Pressured NuVasive, Inc. Stock Today   [Jan-08-18 02:26PM  Motley Fool]
▶ Medtech Player Bounds On Upgrade Amid Tax Reform, Acquisitions   [Jan-04-18 04:31PM  Investor's Business Daily]
▶ ETFs with exposure to NuVasive, Inc. : December 28, 2017   [Dec-28-17 12:31PM  Capital Cube]
▶ Medical device maker says savings from new tax law to fuel innovation and growth   [Dec-21-17 01:46PM  American City Business Journals]
▶ NuVasive To Acquire SafePassage   [Dec-12-17 04:02PM  PR Newswire]
▶ ETFs with exposure to NuVasive, Inc. : November 6, 2017   [Nov-06-17 12:12PM  Capital Cube]
▶ ETFs with exposure to NuVasive, Inc. : October 27, 2017   [Oct-27-17 11:07AM  Capital Cube]
▶ Here's Why NuVasive, Inc. Popped Today   [04:03PM  Motley Fool]
▶ NuVasive's Sluggish Sales Growth Prompts Buybacks   [Oct-24-17 07:19PM  Motley Fool]
▶ NuVasive beats 3Q profit forecasts   [05:33PM  Associated Press]
▶ NuVasive, Inc. to Host Earnings Call   [09:10AM  ACCESSWIRE]
▶ 5 Stocks That Look Good Short   [Oct-22-17 10:00AM  TheStreet.com]
▶ Alphatec Denounces Baseless NuVasive Complaint   [Oct-11-17 09:00AM  GlobeNewswire]
▶ NuVasive acquires startup with Duke University roots   [Sep-22-17 08:50AM  American City Business Journals]
▶ NuVasive Announces Acquisition Of Vertera Spine   [Sep-07-17 10:43AM  PR Newswire]
▶ InfoBionic Appoints Gene Cattarina to Board of Directors   [Aug-22-17 08:00AM  PR Newswire]
▶ ETFs with exposure to NuVasive, Inc. : August 14, 2017   [Aug-14-17 05:04PM  Capital Cube]
Financial statements of NUVA
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.